Setara Biosciences
PrivateLast Round
Series A
Oct 30, 2026
Total Funding Raised
$90M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Setara Biosciences operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in October 2026.
Setara Biosciences is a biotechnology company that develops small molecule precision medicines for rare neuromuscular diseases and other indications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Setara Biosciences Comparables
Compare Setara Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 80% | |
| NMD Pharma | 78% | |
| Celltium | 78% |
For institutional investors. Book with your work email.
Setara Biosciences Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Setara Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series A |
| Deerfield Management | Series A |
| Droia Ventures | Series A |
| Canaan Partners | Series A |
| Euclidean Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 30, 2026
$90M round with participation from Canaan Partners and Deerfield Management.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 30, 2026
Setara Biosciences plans to appoint David Goldstein, PhD, Actio’s founder and a human genetics expert, as President and Executive Chair; he retains his position at Jazz Pharmaceuticals until at least acceptance of the ABS-1230 New Drug Application submission.
- receives_financingOct 30, 2026
On Oct 30th '26, Setara Biosciences, Inc. completes a $90M Series A financing in California to advance precision medicines for severe rare diseases.
For institutional investors. Book with your work email.
Setara Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Setara Biosciences's valuation, stock price, and market status.
Is Setara Biosciences a public or private company?
Setara Biosciences is a private company.
What is the current stock price of Setara Biosciences?
Setara Biosciences is a private company, so its shares have no public market price. Caplight tracks Setara Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Setara Biosciences worth (valuation)?
Valuation information for Setara Biosciences is not publicly available.
Can I buy Setara Biosciences stock?
Setara Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Setara Biosciences's last funding round?
Setara Biosciences's most recent funding round was Series A on October 30, 2026.
Who are the main investors in Setara Biosciences?
Key investors in Setara Biosciences include EcoR1 Capital, Deerfield Management, Droia Ventures, Canaan Partners, Euclidean Capital.
Will Setara Biosciences IPO soon?
No public IPO plans have been announced for Setara Biosciences.
How can I track Setara Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Setara Biosciences's shares on secondary markets.